Bio AI: Harnessing human diversity and AI to build next-generation medicines

At Prellis we integrate human biology with machine learning to discover the next generation of therapeutics. Our bioprinted lymph node organoid (LNO™) platform recaptures the complex biology of the human immune system and allows us to mine the vast diversity of the human antibody repertoire in vitro.

Key Benefits

Hits Hard & High Value Targets

Higher hit rates on tough target classes (e.g. GPCRs) where mouse-based methods often fail. The technology generates large number of initial medicine leads, leading to higher quality medicines.

Human By Design

Lowers immunogenicity risk in patients (ADAs) — reducing clinical failures, which is increasingly important as medicines become more complex.

Fully-integrated Bio AI

The system generates large datasets suitable for training next generation models.

Speed & Agility

Weeks to initial medicine leads, and months to near clinic-ready potent medicines with limited rework.

Our Technology

Prellis’ EXIS™ platform recaptures human immune biology in 3D-printed organoids for the rapid discovery of diverse antibodies for the next generation of therapeutics.

More About Technology

Human Immune Cell Diversity

3D Bioprinted LNO™ Construction

B-cell Activation and Library Creation

Antibody Screening Selection

AI-Guided Screening

AI Optimization

Who We Are

While machine learning is a powerful tool for antibody discovery, its true potential is unlocked when combined with wet lab characterization and confirmation. This synergistic approach defines our unique methodology and sets us apart.

More About Us

Pioneering Discovery

Our EXIS™ platform revolutionizes antibody discovery, integrating natural immune processes and advanced AI to navigate the complexity of the human immune repertoire with unmatched precision and speed.

AI Integration

Artificial intelligence is at the core of our operations, enhancing the identification and optimization of antibodies, streamlining the path from lab to clinic.

Human Immune Replication

By mirroring the human immune response in vitro, we access a vast diversity of antibodies, leveraging the natural repertoire with the benefit of an intrinsically low immunogenic risk profile, for therapeutic innovation.

Bioprinted Organoids

Our advanced two-photon laser bioprinters create organoids with the proper 3D structure to recapture the complex biology of immune responses in vitro.

Diverse Antibody Library

We tap into the genetic diversity of multiple donors, creating an extensive library of fully human antibodies, each with the potential to become a life-saving therapy.

Innovative Partnerships

Strategic collaborations amplify our impact, pairing our technological strengths with leading biotech and pharmaceutical partners to accelerate therapeutic development.

Partner with Us

Prellis utilizes its unique expertise and advanced technology to make significant strides in the design and development of novel therapeutic agents that can contribute to enhanced treatment outcomes for a variety of diseases.

Partnering